• Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplinary Molecular Biology Meeting of Eastern PACA

  NCT06606366

  RecruitingInterventionalNot ApplicableUpdated Jul 20, 2026
• Implementation of Liquid Biopsies During Routine Clinical Care in Patients With Advanced Malignancies (LIQPLAT)

  NCT06367751

  Active, not recruitingInterventionalNot ApplicableUpdated Mar 11, 2026
• Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy Selection

  NCT05585684

  RecruitingObservationalUpdated Nov 20, 2025
• CIRculating CANcer MAster-Protocol

  NCT05089747

  RecruitingObservationalUpdated Jun 10, 2026
• Liquid Biopsies and IMAging for Improved Cancer Care

  NCT04224779

  Active, not recruitingInterventionalNot ApplicableUpdated Feb 12, 2025
• LIquid BIopsies in Patients Presenting Non-small Cell Lung Cancer

  NCT02511288

  RecruitingObservationalUpdated Aug 21, 2024

ClinicalTrials.gov ID

NCT05283044

Lead Sponsor

Gustave Roussy, Cancer Campus, Grand ParisOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

10,000Estimated

Last Update Posted

Jun 25, 2025Actual

Start Date

Jun 29, 2022Actual

Primary Completion Date

Nov 15, 2028Estimated

Completion Date

Apr 15, 2030Estimated

Official Title

Implementing Precision Medicine in cOmmunity HospiTALs

Brief Summary

This is a prospective biomarker study that aims at demonstrating the impact of liquid biopsy to deliver better treatment for cancer patients with metastatic disease managed in the community setting

Detailed Description

Patients will be selected to present a metastatic cancer (de novo or relapse after primary tumor treatment) eligible for a first line treatment (chemotherapy, immunotherapy, endocrine therapy or targeted therapy).

All tumor subtype could be enrolled in the study; metastatic prostate cancer must be resistant to castration. Triple negative breast cancer and Hormone receptor positive, Her2-negative metastatic breast cancer resistant to endocrine therapy are eligible to the study.

A plasma sample will be collected at baseline and will be tested for a large panel of gene and MSI status using Next Generation Sequencing (NGS) (cf table). Results will be discussed within a Molecular Tumor Board (MTB) with all declared centers.

• Metastatic Cancer

• biopsy liquid

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

Yes

Eligibility Criteria

Inclusion Criteria:

Participants are eligible to be included in the study only if they meet all of the following criteria:

1. Age ≥ 18 years
2. Histology: solid malignant tumor
3. Locally advanced/unresectable and/or metastatic (for prostate cancer: castration resistant prostate cancer, for RH+/HER2- breast cancer: prior treatment with endocrine therapy plus anti-CDK4/6 inhibitor)
4. Eastern Cooperative Oncology Group (ECOG) performance status < 2
5. Measurable disease as per RECIST criteria
6. Patient with a social security in compliance with the French law relating to biomedical research (Article L.1121-11 of French Public Health Code)
7. Voluntary signed and dated written informed consent prior to any study specific procedure.

Exclusion Criteria:

Participants will be excluded from the study if they meet any of the following criteria:

1. Radiological evidence of symptomatic or progressive brain metastases
2. Previous or current malignancies of others histologies within the last 2 years, with the exception of in situ carcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin and prostate cancer
3. Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in a clinical trial or which would jeopardize compliance with the protocol
4. Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent
5. Minors (Age < 18 years)
6. Pregnant or breast-feeding women
7. Previous enrollment in the present study.

Primary Purpose

Other

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

Gustave Roussy, Cancer Campus, Grand ParisOTHER

I.ALEXANDRE@chbligny.fr